James R. Hollingshead

President and Chief Executive Officer at INSULET

Board

Since June 1, 2022

Age

61 years

Education

Earned a Bachelor of Arts in History and International Relations with Highest Distinction from Stanford University and a Master’s Degree and Ph.D. in Political Science from the University of California, Berkeley.

Tenure

Joined the board in July 2019 and was appointed President and Chief Executive Officer on June 1, 2022.

Also at INSULET

AMC

Ana Maria Chadwick

EVP, Chief Financial Officer and Treasurer

Dan Manea

SVP, Chief Human Resources Officer

Eric Benjamin

EVP, Chief Product and Customer Experience Officer

About

James R. Hollingshead has built a distinguished career as a leader in both consulting and digital transformation. His early work in strategy consulting at Deloitte Consulting and as Managing Partner at Monitor Group provided him with deep insights into biotech, high-tech, and telecommunications industries.

He later led major digital transformation initiatives at ResMed, where he was pivotal in shifting a traditional medical hardware technology model to a SaaS-based digital solutions framework. This experience underscores his ability to drive innovation in complex, regulated environments.

At Insulet, his leadership as President and Chief Executive Officer reinforces his commitment to strategic growth and digital innovation. His ongoing contributions continuously shape the company's direction in the healthcare and medical device sectors.

$PODD Performance Under James R. Hollingshead

Past Roles

Organization	Role	Date Range	Details
Insulet Corporation (PODD)	Director on the Board	July 2019 - June 1, 2022	Served as director before promotion to President and CEO
ResMed, Inc.	President, Sleep and Respiratory Care (SRC) business	July 2020 - May 2022	Led the transformation to digital SaaS-based solutions
Deloitte Consulting	Senior Partner in the Strategy and Life Sciences practices	N/A	Worked across multiple industries including biotech, high-tech, and telecommunications
Monitor Group	Managing Partner	N/A	Focused on strategy consulting initiatives
Various Companies	Other Strategy Consulting Roles	N/A	Accumulated nearly two decades of experience in strategy consulting across industries

Fixed Compensation

Data from FY 2023

Component Name	Amount	Payment Schedule	Additional Details
Base Salary	$850,000	Annual	Fixed annual base salary
All Other Compensation	$9,900	Annual	Fixed component for additional payments

Performance Compensation

Data from FY 2023

Annual Incentive Compensation (AIP)

Metric	Weight	Threshold	Target	Stretch Goal	Maximum	Details/Notes
Adjusted Revenue	60%	90% of target (50% payout)	100% (100% payout)	104.5% (130% payout)	110% (200% payout)	Part of financial metrics (80% of AIP)
Adjusted EBIT	20%	85% of target (50% payout)	100% (100% payout)	104.5% (130% payout)	115% (200% payout)
New Customer Starts	6.7%	N/A	N/A	N/A	N/A	Part of strategic metrics (20% of AIP)
Innovation Pipeline	6.7%	N/A	N/A	N/A	N/A
People and Culture	6.7%	N/A	N/A	N/A	N/A

Overall Weighted Payout Factor: 198.8% leading to a final payout of $2,027,760.
Grant Details: Date: Feb 28, 2023; Target Award: $1,020,000; Maximum Award: $2,040,000; Grant Date Stock Price: $276.36.

Performance Stock Units (PSUs)

Metric	Weight	Threshold	Target	Stretch Goal	Maximum	Details/Notes
Adjusted Revenue	70%	90% of target (50% payout)	100% (100% payout)	104.5% (130% payout)	110% (200% payout)	Measured over FY23-FY25
Adjusted EBIT	30%	85% of target (50% payout)	100% (100% payout)	104.5% (130% payout)	115% (200% payout)

Vesting: Occurs after the FY23-FY25 performance cycle ending Dec 31, 2025.
Grant Details: Date: Feb 28, 2023; Fair Value: $5,699,925; Grant Date Stock Price: $276.36.

Stock Options

Grant Date: Feb 28, 2023.
Grant Date Fair Value: $1,899,897.
Exercise Price: $276.36 per share.
Vesting: 25% annually, starting on Feb 28, 2024.
Expiration: Feb 28, 2033.
Note: No specific performance metrics; value depends on the company’s stock price exceeding the exercise price.

Long-Term Incentive Award Allocation

Component	Allocation %	Target/Quantity	Vesting Schedule	Details/Notes
PSUs	60%	20,625 shares (target); 41,250 shares (max)	Vest after FY23-FY25 performance cycle	Based on cumulative Adjusted Revenue (70%) & Adjusted EBIT (30%)
RSUs	20%	6,875 shares	One-third annually over 3 years
Stock Options	20%	16,475 options	25% annually over 4 years	Exercise Price: $276.36 per share ; part of the long-term award allocation